Kathryn Nicole Weaver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kathryn Nicole Weaver has a total of 277 co-authors. Here are the top co-authors by number of shared publications:
Robert J. Hopkin
Division of Human Genetics Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
6 shared publicationsAmy Shikany
Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
5 shared publications- Elizabeth K. Baker
Atrium Health Levine Children's Hospital, 1000 Blythe Blvd, Charlotte, NC, 28203, USA; Wake Forest School of Medicine, 915 Pearl Park Wy, Charlotte, NC, 28204, USA
5 shared publications - Robert J. Hopkin
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
5 shared publications Rolf W. Stottmann
Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University School of Medicine, Columbus, OH, USA
5 shared publicationsHoward M. Saal
Division of Human Genetics Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
4 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (3) , 100626
Combined skeletal dysplasia and vasculopathy phenotypes associated with in-frame intragenic deletion in PRKACA
- 18 May 2026
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (3) , 100626
Open AccessCombined skeletal dysplasia and vasculopathy phenotypes associated with in-frame intragenic deletion in PRKACA
- Open Access
- 30 March 2026
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (3) , 100598
A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy
- 30 March 2026
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 7 (3) , 100598
Open AccessA homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (1) , e005578
MEK Inhibition Improves Clinical Outcome in Premature Infants With Multisystemic RASA1 Disease
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (1) , e005578
MEK Inhibition Improves Clinical Outcome in Premature Infants With Multisystemic RASA1 Disease
- Open Access
- 21 July 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-8
Sequencing validates deep learning models for EHR-based detection of Noonan syndrome in pediatric patients
Despite advanced diagnostic tools, early detection of rare genetic conditions like Noonan syndrome (NS) remains challenging. We evaluated a deep learning model’s real-world performance in identifying potential NS cases using electronic health record (EHR) data, validated through genetic sequencing and clinical assessment. The model analyzed 92,428 patients, identifying 171 high-risk individuals (score > 0.8) who underwent comprehensive review. Among these, 86 had prior genetic diagnoses, including three NS cases diagnosed during the study period. Genetic sequencing of remaining patients identified two additional NS cases with pathogenic variants. The model achieved 2.92% precision and 99.82% specificity. While precision was lower than prior validation (33.3%), this reflected expected differences in disease prevalence rather than model degradation. NS-associated phenotypes were enriched among high-risk patients, and trajectory analysis showed potential for earlier identification, highlighting both promise and limitations of EHR-based computational screening tools.
- 21 July 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-8
Open AccessSequencing validates deep learning models for EHR-based detection of Noonan syndrome in pediatric patients
Despite advanced diagnostic tools, early detection of rare genetic conditions like Noonan syndrome (NS) remains challenging. We evaluated a deep learning model’s real-world performance in identifying potential NS cases using electronic health record (EHR) data, validated through genetic sequencing and clinical assessment. The model analyzed 92,428 patients, identifying 171 high-risk individuals (score > 0.8) who underwent comprehensive review. Among these, 86 had prior genetic diagnoses, including three NS cases diagnosed during the study period. Genetic sequencing of remaining patients identified two additional NS cases with pathogenic variants. The model achieved 2.92% precision and 99.82% specificity. While precision was lower than prior validation (33.3%), this reflected expected differences in disease prevalence rather than model degradation. NS-associated phenotypes were enriched among high-risk patients, and trajectory analysis showed potential for earlier identification, highlighting both promise and limitations of EHR-based computational screening tools.
- 30 November 2024
- Published by Springer Nature
- p. 307-317
Comprehensive Care for Patients with RASopathies
- 30 November 2024
- Published by Springer Nature
- p. 307-317
Comprehensive Care for Patients with RASopathies
- Open Access
- 31 October 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9537
RMND1 and PLN variants are the underlying cause of Perrault‐like syndrome and cardiac anomalies in a patient
Key Clinical Message: Recent studies have established an association between RMND1 variants and Perrault syndrome. In this case report, we present a female patient with Perrault syndrome and cardiomyopathy, resulting from variants in RMND1 and PLN , respectively.
- 31 October 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (11) , e9537
Open AccessRMND1 and PLN variants are the underlying cause of Perrault‐like syndrome and cardiac anomalies in a patient
Key Clinical Message: Recent studies have established an association between RMND1 variants and Perrault syndrome. In this case report, we present a female patient with Perrault syndrome and cardiomyopathy, resulting from variants in RMND1 and PLN , respectively.
- Open Access
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1412806
Genetic investigation and diagnosis in adults with congenital heart disease with or without structural or neurodevelopmental comorbidity: a retrospective chart review
Introduction: Genetic evaluation is indicated for individuals with congenital heart disease (CHD), especially if extracardiac anomalies are also present. Timely recognition of genetic diagnoses can facilitate medical management and as well as provide assessment of reproductive risk. At least 20% of the pediatric population with CHD has a syndrome or genetic diagnosis. Further, at least 30% have extracardiac congenital malformations and/or neurodevelopmental differences (NDD), and this is known to increase the likelihood of a genetic/syndromic diagnosis. However, little is known regarding whether these statistics also apply to the current population of adults living with CHD, many of whom were born prior to currently available genetic testing.Methods: The primary aim of this study was to determine the prevalence of documented genetic and syndromic diagnoses in a cohort of adults with CHD followed by a dedicated adult CHD (ACHD) clinic. The secondary aims were to describe genetic testing and genetic referral patterns in this population and identify the presence of extracardiac comorbidities which are known to be indicative of an underlying genetic diagnosis in the pediatric CHD population. To answer these questions, we performed a retrospective chart review on a sample of adults with CHD (excluding those with isolated bicuspid aortic valve) seen at Cincinnati Children’s Hospital in the ACHD clinic between 2010–2021.Results: Among 233 adult CHD patients, 36 (14%) had a documented genetic or syndromic diagnosis but only 29 (13.7%) had received genetic testing, while 27 (11.6%) had received genetic referrals. Furthermore, of 170 patients without any documented genetics related care (defined as genetic testing, genetic referrals, or genetic diagnosis), 35 (20%) had at least one congenital and/or neurodevelopmental comorbidity. Factors associated with individuals having received genetics related care included younger age (<40), male sex, and presence of extracardiac comorbidities.Discussion: Our results indicate important gaps in genetics-related care for adults living with CHD. The subset of our cohort with congenital and/or neurodevelopmental comorbidities who received no genetic-related care, represent a population of adults with CHD who may have unrecognized genetic diagnoses.
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 15, 1412806
Open AccessGenetic investigation and diagnosis in adults with congenital heart disease with or without structural or neurodevelopmental comorbidity: a retrospective chart review
Introduction: Genetic evaluation is indicated for individuals with congenital heart disease (CHD), especially if extracardiac anomalies are also present. Timely recognition of genetic diagnoses can facilitate medical management and as well as provide assessment of reproductive risk. At least 20% of the pediatric population with CHD has a syndrome or genetic diagnosis. Further, at least 30% have extracardiac congenital malformations and/or neurodevelopmental differences (NDD), and this is known to increase the likelihood of a genetic/syndromic diagnosis. However, little is known regarding whether these statistics also apply to the current population of adults living with CHD, many of whom were born prior to currently available genetic testing.Methods: The primary aim of this study was to determine the prevalence of documented genetic and syndromic diagnoses in a cohort of adults with CHD followed by a dedicated adult CHD (ACHD) clinic. The secondary aims were to describe genetic testing and genetic referral patterns in this population and identify the presence of extracardiac comorbidities which are known to be indicative of an underlying genetic diagnosis in the pediatric CHD population. To answer these questions, we performed a retrospective chart review on a sample of adults with CHD (excluding those with isolated bicuspid aortic valve) seen at Cincinnati Children’s Hospital in the ACHD clinic between 2010–2021.Results: Among 233 adult CHD patients, 36 (14%) had a documented genetic or syndromic diagnosis but only 29 (13.7%) had received genetic testing, while 27 (11.6%) had received genetic referrals. Furthermore, of 170 patients without any documented genetics related care (defined as genetic testing, genetic referrals, or genetic diagnosis), 35 (20%) had at least one congenital and/or neurodevelopmental comorbidity. Factors associated with individuals having received genetics related care included younger age (<40), male sex, and presence of extracardiac comorbidities.Discussion: Our results indicate important gaps in genetics-related care for adults living with CHD. The subset of our cohort with congenital and/or neurodevelopmental comorbidities who received no genetic-related care, represent a population of adults with CHD who may have unrecognized genetic diagnoses.
- Open Access
- 19 September 2024
- Published by Wiley
RMND1 and PLN variants are the underlying cause of Perrault-like syndrome and cardiac anomalies in a patient
- 19 September 2024
- Published by Wiley
Open AccessRMND1 and PLN variants are the underlying cause of Perrault-like syndrome and cardiac anomalies in a patient
- 18 October 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (4) , 815-821
Phenotypes and genotypes in a cohort of children with single-ventricle CHD
Objective: CHD is known to be associated with increased risk for neurodevelopmental disorders. The combination of CHD with neurodevelopmental disorders and/or extra-cardiac anomalies increases the chance for an underlying genetic diagnosis. Over the last 15 years, there has been a dramatic increase in the use of broad-scale genetic testing. We sought to determine if neurodevelopmental disorders in children with single-ventricle CHD born prior to the genetic testing revolution are associated with genetic diagnosis.Methods: We identified 74 5–12-year-old patients with single-ventricle CHD post-Fontan procedure. We retrospectively evaluated genetic testing performed and neurodevelopmental status of these patients.Results: In this cohort, there was an overall higher rate of neurodevelopmental disorders (80%) compared to the literature (50%). More of the younger (5–7-year-old) patients were seen by genetic counsellors compared to the older (8–12-year-old) cohort (46% versus 19% p value = 0.01). In the younger cohort, the average age of initial consultation was 7.7 days compared to 251 days in the older cohort. The overall rate of achieving a molecular diagnosis was 12% and 8% in the younger and older cohorts, respectively; however, the vast majority of did not have broad genetic testing.Conclusion: The minority of patients in our cohort achieved a genetic diagnosis. Given a large increase in the number of genes associated with monogenic CHD and neurodevelopmental disorders in the last decade, comprehensive testing and consultation with clinical genetics should be considered in this age range, since current testing standards did not exist during their infancy.
- 18 October 2023
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 34 (4) , 815-821
Phenotypes and genotypes in a cohort of children with single-ventricle CHD
Objective: CHD is known to be associated with increased risk for neurodevelopmental disorders. The combination of CHD with neurodevelopmental disorders and/or extra-cardiac anomalies increases the chance for an underlying genetic diagnosis. Over the last 15 years, there has been a dramatic increase in the use of broad-scale genetic testing. We sought to determine if neurodevelopmental disorders in children with single-ventricle CHD born prior to the genetic testing revolution are associated with genetic diagnosis.Methods: We identified 74 5–12-year-old patients with single-ventricle CHD post-Fontan procedure. We retrospectively evaluated genetic testing performed and neurodevelopmental status of these patients.Results: In this cohort, there was an overall higher rate of neurodevelopmental disorders (80%) compared to the literature (50%). More of the younger (5–7-year-old) patients were seen by genetic counsellors compared to the older (8–12-year-old) cohort (46% versus 19% p value = 0.01). In the younger cohort, the average age of initial consultation was 7.7 days compared to 251 days in the older cohort. The overall rate of achieving a molecular diagnosis was 12% and 8% in the younger and older cohorts, respectively; however, the vast majority of did not have broad genetic testing.Conclusion: The minority of patients in our cohort achieved a genetic diagnosis. Given a large increase in the number of genes associated with monogenic CHD and neurodevelopmental disorders in the last decade, comprehensive testing and consultation with clinical genetics should be considered in this age range, since current testing standards did not exist during their infancy.
- Open Access
- 29 September 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (2) , 195-202
Prenatal and infantile diagnosis of craniosynostosis in individuals with RASopathies
Fetuses with RASopathies can have a wide variety of anomalies including increased nuchal translucency, hydrops fetalis, and structural anomalies (typically cardiac and renal). There are few reports that describe prenatal‐onset craniosynostosis in association with a RASopathy diagnosis. We present clinical and molecular characteristics of five individuals with RASopathy and craniosynostosis. Two were diagnosed with craniosynostosis prenatally, 1 was diagnosed as a neonate, and 2 had evidence of craniosynostosis noted as neonates without formal diagnosis until later. Two of these individuals have Noonan syndrome ( PTPN11 and KRAS variants) and three individuals have Cardiofaciocutaneous syndrome ( KRAS variants). Three individuals had single suture synostosis and two had multiple suture involvement. The most common sutures involved were sagittal ( n = 3), followed by coronal ( n = 3), and lambdoid ( n = 2) sutures. This case series confirms craniosynostosis as one of the prenatal findings in individuals with RASopathies and emphasizes the importance of considering a RASopathy diagnosis in fetuses with multiple anomalies in combination with craniosynostosis.
- 29 September 2023
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 194 (2) , 195-202
Open AccessPrenatal and infantile diagnosis of craniosynostosis in individuals with RASopathies
Fetuses with RASopathies can have a wide variety of anomalies including increased nuchal translucency, hydrops fetalis, and structural anomalies (typically cardiac and renal). There are few reports that describe prenatal‐onset craniosynostosis in association with a RASopathy diagnosis. We present clinical and molecular characteristics of five individuals with RASopathy and craniosynostosis. Two were diagnosed with craniosynostosis prenatally, 1 was diagnosed as a neonate, and 2 had evidence of craniosynostosis noted as neonates without formal diagnosis until later. Two of these individuals have Noonan syndrome ( PTPN11 and KRAS variants) and three individuals have Cardiofaciocutaneous syndrome ( KRAS variants). Three individuals had single suture synostosis and two had multiple suture involvement. The most common sutures involved were sagittal ( n = 3), followed by coronal ( n = 3), and lambdoid ( n = 2) sutures. This case series confirms craniosynostosis as one of the prenatal findings in individuals with RASopathies and emphasizes the importance of considering a RASopathy diagnosis in fetuses with multiple anomalies in combination with craniosynostosis.